Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease
- PMID: 18391196
- PMCID: PMC2311361
- DOI: 10.1073/pnas.0801677105
Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease
Abstract
The long-term goal of nuclear transfer or alternative reprogramming approaches is to create patient-specific donor cells for transplantation therapy, avoiding immunorejection, a major complication in current transplantation medicine. It was recently shown that the four transcription factors Oct4, Sox2, Klf4, and c-Myc induce pluripotency in mouse fibroblasts. However, the therapeutic potential of induced pluripotent stem (iPS) cells for neural cell replacement strategies remained unexplored. Here, we show that iPS cells can be efficiently differentiated into neural precursor cells, giving rise to neuronal and glial cell types in culture. Upon transplantation into the fetal mouse brain, the cells migrate into various brain regions and differentiate into glia and neurons, including glutamatergic, GABAergic, and catecholaminergic subtypes. Electrophysiological recordings and morphological analysis demonstrated that the grafted neurons had mature neuronal activity and were functionally integrated in the host brain. Furthermore, iPS cells were induced to differentiate into dopamine neurons of midbrain character and were able to improve behavior in a rat model of Parkinson's disease upon transplantation into the adult brain. We minimized the risk of tumor formation from the grafted cells by separating contaminating pluripotent cells and committed neural cells using fluorescence-activated cell sorting. Our results demonstrate the therapeutic potential of directly reprogrammed fibroblasts for neuronal cell replacement in the animal model.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Potential application of induced pluripotent stem cells in cell replacement therapy for Parkinson's disease.CNS Neurol Disord Drug Targets. 2011 Jun;10(4):449-58. doi: 10.2174/187152711795563994. CNS Neurol Disord Drug Targets. 2011. PMID: 21495962 Review.
-
Human induced pluripotent stem cell-derived neurons improve motor asymmetry in a 6-hydroxydopamine-induced rat model of Parkinson's disease.Cytotherapy. 2015 May;17(5):665-79. doi: 10.1016/j.jcyt.2015.02.001. Epub 2015 Mar 5. Cytotherapy. 2015. PMID: 25747741
-
Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripotent stem cells and inhibits teratoma formation in rats with Parkinson-like pathology.Cell Transplant. 2012;21(1):313-32. doi: 10.3727/096368911X580572. Epub 2011 Jun 7. Cell Transplant. 2012. PMID: 21669041
-
Direct reprogramming of rat neural precursor cells and fibroblasts into pluripotent stem cells.PLoS One. 2010 Mar 24;5(3):e9838. doi: 10.1371/journal.pone.0009838. PLoS One. 2010. PMID: 20352099 Free PMC article.
-
Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors.Cell Prolif. 2008 Feb;41 Suppl 1(Suppl 1):51-6. doi: 10.1111/j.1365-2184.2008.00493.x. Cell Prolif. 2008. PMID: 18181945 Free PMC article. Review.
Cited by
-
Regenerative rehabilitation: a novel multidisciplinary field to maximize patient outcomes.Med Rev (2021). 2024 Jun 14;4(5):413-434. doi: 10.1515/mr-2023-0060. eCollection 2024 Oct. Med Rev (2021). 2024. PMID: 39444794 Free PMC article. Review.
-
Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells (iPSC) in precision cell therapies.Int J Surg. 2024 Jul 4;110(10):6432-55. doi: 10.1097/JS9.0000000000001892. Online ahead of print. Int J Surg. 2024. PMID: 38963728 Free PMC article.
-
Glial-restricted progenitor cells: a cure for diseased brain?Biol Res. 2024 Mar 12;57(1):8. doi: 10.1186/s40659-024-00486-1. Biol Res. 2024. PMID: 38475854 Free PMC article. Review.
-
Cell Therapy for Parkinson's Disease.Pharmaceutics. 2023 Nov 22;15(12):2656. doi: 10.3390/pharmaceutics15122656. Pharmaceutics. 2023. PMID: 38139997 Free PMC article. Review.
-
iPSCs-Derived Neurons and Brain Organoids from Patients.Handb Exp Pharmacol. 2023;281:59-81. doi: 10.1007/164_2023_657. Handb Exp Pharmacol. 2023. PMID: 37306818
References
-
- Lerou PH, Daley GQ. Therapeutic potential of embryonic stem cells. Blood Rev. 2005;19:321–331. - PubMed
-
- Hochedlinger K, Jaenisch R. Nuclear transplantation, embryonic stem cells, and the potential for cell therapy. N Engl J Med. 2003;349:275–286. - PubMed
-
- Jaenisch R. Human cloning: The science and ethics of nuclear transplantation. N Engl J Med. 2004;351:2787–2791. - PubMed
-
- Weissman IL. Medicine: Politic stem cells. Nature. 2006;439:145–147. - PubMed
-
- Rideout WM, III, Hochedlinger K, Kyba M, Daley GQ, Jaenisch R. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell. 2002;109:17–27. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
